KDventures: Safety Pause at Modus Delays Readout - Redeye

Modus has temporarily paused enrolment in part 2 of its phase IIa study of sevuparin in CKD with anaemia after a serious adverse event in one patient, reported as a SUSAR. The proof-of-concept readout moves from around the turn of the year to Q1 2027. Modus is a small part of KDventures’ NAV, so the direct valuation effect is limited.

Länk till analysen i sin helhet: https://www.redeye.se/research/1187521/kdventures-safety-pause-at-modus-delays-readout?utm_source=finwire&utm_medium=RSS